ASPARGO

Prior to co-founding Aspargo Labs in 2019, Michael served as COO, CFO and member of the Board of Directors of Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer therapeutics that are intended to be broadly effective across tumor types and have tolerable toxicity profiles. At Tyme, Michael was instrumental in raising over 50 million dollars and obtaining a public listing on NASDAQ.

During his career, Michael has held positions in finance, manufacturing, sales & marketing, logistics and general management. He has experience in taking companies public, raising funds in public and private markets with both retail and institutional investors.

Mr. Demurjian served as CEO of Luminant Biosciences, an oncology research company studying metabolic pathways to destroying cancer cells. Mr. Demurjian has successfully completed strategic transactions with G.E., Stryker, Black & Decker Corp. and Crane Cams. Mr. Demurjian currently sits on the Board of Directors of the Susan G. Komen Foundation, NYU and has served in the past on the Board of Directors of Luminant Bio., Mikronite Tech & KCC.